These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22926257

  • 1. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L.
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [Abstract] [Full Text] [Related]

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.
    Cancer; 2000 Mar 15; 88(6):1384-92. PubMed ID: 10717621
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 2000 Oct 15; 83(7):906-13. PubMed ID: 10970693
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K.
    Cancer Res; 1994 Nov 15; 54(22):5895-901. PubMed ID: 7954420
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G.
    Clin Cancer Res; 2005 Jan 01; 11(1):49-57. PubMed ID: 15671527
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H, Schally AV, Sun B, Armatis P, Groot K.
    Oncogene; 1999 Nov 25; 18(50):7168-73. PubMed ID: 10597318
    [Abstract] [Full Text] [Related]

  • 8. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
    Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV.
    Cancer Res; 1994 Feb 15; 54(4):1035-41. PubMed ID: 8313359
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV.
    Cancer; 1994 Feb 15; 73(4):1229-38. PubMed ID: 8313327
    [Abstract] [Full Text] [Related]

  • 11. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV.
    Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934
    [Abstract] [Full Text] [Related]

  • 12. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F.
    Cell Cycle; 2012 Jul 01; 11(13):2518-25. PubMed ID: 22751419
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B.
    Cancer Res; 1991 Nov 01; 51(21):5980-6. PubMed ID: 1682039
    [Abstract] [Full Text] [Related]

  • 14. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
    Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, Moder A, Aigner E, Datz C, Halmos G.
    Proc Natl Acad Sci U S A; 2007 Nov 20; 104(47):18671-6. PubMed ID: 18003891
    [Abstract] [Full Text] [Related]

  • 15. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Oncol; 2007 Apr 20; 30(4):1019-28. PubMed ID: 17332943
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 18. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G.
    Anticancer Drugs; 2008 Apr 28; 19(4):349-58. PubMed ID: 18454045
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S, Miller G, Schally AV.
    Cancer Res; 1991 Nov 01; 51(21):6006-9. PubMed ID: 1682040
    [Abstract] [Full Text] [Related]

  • 20. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.